Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Editas Medicine, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 78 | 20 | 26 | 91 | 21 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 78 | 20 | 26 | 91 | 21 |
Selling & Adminstrative & Depr. & Amort Expenses | 247 | 246 | 219 | 226 | 161 |
Income After Depreciation & Amortization | -169 | -226 | -193 | -135 | -141 |
Non-Operating Income | 16 | 4 | 2 | 3 | 0 |
Interest Expense | 0 | -1 | 2 | -16 | -7 |
Pretax Income | -153 | -220 | -193 | -116 | -134 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -153 | -220 | -193 | -116 | -134 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -153 | -220 | -193 | -116 | -134 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -168 | -220 | -188 | -131 | -138 |
Depreciation & Amortization (Cash Flow) | 1 | 6 | 5 | 4 | 3 |
Income After Depreciation & Amortization | -169 | -226 | -193 | -135 | -141 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 75.97 | 68.67 | 67.62 | 58.61 | 49.98 |
Diluted EPS Before Non-Recurring Items | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 |
Diluted Net EPS (GAAP) | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 |
Fiscal Year end for Editas Medicine, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.51 | 1.14 | 60.05 | 5.34 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.51 | 1.14 | 60.05 | 5.34 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 72.42 | 68.13 | 84.02 | 55.50 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -71.91 | -66.99 | -23.97 | -50.16 |
Non-Operating Income | NA | 0.00 | 5.04 | 3.50 | 5.14 |
Interest Expense | NA | -4.30 | -0.01 | -1.59 | 0.00 |
Pretax Income | NA | -67.61 | -61.95 | -18.87 | -45.02 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -67.61 | -61.95 | -18.87 | -45.02 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -67.61 | -61.95 | -18.87 | -45.02 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 82.31 | 81.94 | 81.71 | 81.65 |
Diluted EPS Before Non-Recurring Items | NA | -0.82 | -0.76 | -0.23 | -0.55 |
Diluted Net EPS (GAAP) | NA | -0.82 | -0.76 | -0.20 | -0.55 |